Flt3L blockade did not have any effect on tumor growth or survival when administered alone, but tumor progression was controlled (p < 0.05) and survival was prolonged (p < 0.05) when combined with RT and anti-TIGIT treatment (Fig. 8b–c). Here, FLT3LG is linked to neoplasm.